Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Divided Doses for Methadone Maintenance

Divided Doses for Methadone Maintenance Opioid dependence, when untreated, typically progresses in a downhill course. Periods of remission are, more often than not, followed by a return to drug use accompanied by psychiatric and medical morbidity, incarceration, and frequently death. Opioid agonist therapy has proven to be a highly effective treatment for this otherwise highly morbid disorder (1). Both methadone and buprenorphine dramatically attenuate the painful drug craving experienced during opioid withdrawal and abstinence, thus mitigating the perceived need for the drug. Key components of agonist therapies are their oral formulation and long half-life, allowing once-a-day dosing in a clinic or outpatient setting. Nevertheless, a sizable number of patients who undergo agonist therapy persist in their illicit opioid use despite medication compliance. Continued, or a return to, opioid use during agonist therapy is often the result of breakthrough craving. When this occurs, increasing the agonist dose is typically the most appropriate intervention. For a small number of patients, breakthrough craving occurs because of 1) a genetic variant of the P450 3A4 or 2D6 enzymes, which increases methadone metabolism; 2) the concomitant use of other medications or alcohol that also induces P450; or 3) the hypermetabolism and increased volume of distribution during pregnancy. These http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Psychiatry American Psychiatric Publishing, Inc (Journal)

Divided Doses for Methadone Maintenance

American Journal of Psychiatry , Volume 165 (3): 303 – Mar 1, 2008

Divided Doses for Methadone Maintenance

American Journal of Psychiatry , Volume 165 (3): 303 – Mar 1, 2008

Abstract

Opioid dependence, when untreated, typically progresses in a downhill course. Periods of remission are, more often than not, followed by a return to drug use accompanied by psychiatric and medical morbidity, incarceration, and frequently death. Opioid agonist therapy has proven to be a highly effective treatment for this otherwise highly morbid disorder (1). Both methadone and buprenorphine dramatically attenuate the painful drug craving experienced during opioid withdrawal and abstinence, thus mitigating the perceived need for the drug. Key components of agonist therapies are their oral formulation and long half-life, allowing once-a-day dosing in a clinic or outpatient setting. Nevertheless, a sizable number of patients who undergo agonist therapy persist in their illicit opioid use despite medication compliance. Continued, or a return to, opioid use during agonist therapy is often the result of breakthrough craving. When this occurs, increasing the agonist dose is typically the most appropriate intervention. For a small number of patients, breakthrough craving occurs because of 1) a genetic variant of the P450 3A4 or 2D6 enzymes, which increases methadone metabolism; 2) the concomitant use of other medications or alcohol that also induces P450; or 3) the hypermetabolism and increased volume of distribution during pregnancy. These

Loading next page...
 
/lp/american-psychiatric-publishing-inc-journal/divided-doses-for-methadone-maintenance-t3f32i4rrG

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Psychiatric Publishing, Inc (Journal)
Copyright
Copyright © 2008 American Psychiatric Association. All rights reserved.
ISSN
0002-953X
DOI
10.1176/appi.ajp.2007.07121944
pmid
18316426
Publisher site
See Article on Publisher Site

Abstract

Opioid dependence, when untreated, typically progresses in a downhill course. Periods of remission are, more often than not, followed by a return to drug use accompanied by psychiatric and medical morbidity, incarceration, and frequently death. Opioid agonist therapy has proven to be a highly effective treatment for this otherwise highly morbid disorder (1). Both methadone and buprenorphine dramatically attenuate the painful drug craving experienced during opioid withdrawal and abstinence, thus mitigating the perceived need for the drug. Key components of agonist therapies are their oral formulation and long half-life, allowing once-a-day dosing in a clinic or outpatient setting. Nevertheless, a sizable number of patients who undergo agonist therapy persist in their illicit opioid use despite medication compliance. Continued, or a return to, opioid use during agonist therapy is often the result of breakthrough craving. When this occurs, increasing the agonist dose is typically the most appropriate intervention. For a small number of patients, breakthrough craving occurs because of 1) a genetic variant of the P450 3A4 or 2D6 enzymes, which increases methadone metabolism; 2) the concomitant use of other medications or alcohol that also induces P450; or 3) the hypermetabolism and increased volume of distribution during pregnancy. These

Journal

American Journal of PsychiatryAmerican Psychiatric Publishing, Inc (Journal)

Published: Mar 1, 2008

There are no references for this article.